MetLife (MET) Q2 Earnings and Revenues Miss Estimates

MetLife (MET) reported Q2 adjusted earnings of $2.02 per share, missing the Zacks Consensus Estimate of $2.19 by 7.76%, and revenues of $17.92 billion, falling short of expectations by 2.58%. This marks the fourth consecutive quarter the insurer has missed EPS estimates, contributing to an 8.5% year-to-date share decline compared to the S&P 500's 7.1% gain. With unfavorable estimate revisions resulting in a Zacks Rank #4 (Sell), the stock is anticipated to underperform in the near term, with future price action largely contingent on management's upcoming commentary.

Analysis

MetLife's second-quarter results reveal significant operational headwinds, with the company failing to meet consensus estimates on both top and bottom lines. Quarterly adjusted earnings of $2.02 per share represented a material 7.76% miss against the $2.19 estimate and a decline from $2.28 in the prior-year period. This marks the fourth consecutive quarter that MetLife has failed to surpass EPS expectations, establishing a negative trend. Revenues also contracted year-over-year to $17.92 billion from $18.68 billion, missing forecasts by 2.58%. This persistent underperformance has directly contributed to the stock's 8.5% year-to-date decline, a stark contrast to the S&P 500's 7.1% gain. The market's dim view is further reinforced by an unfavorable trend in earnings estimate revisions leading into the report, culminating in a Zacks Rank #4 (Sell) designation, which signals an expectation of continued near-term market underperformance. The sustainability of the stock's price will now heavily depend on management's ability to provide a convincing strategic outlook during the upcoming earnings call.

Key Decisions for Investors

• Given the fourth consecutive earnings miss and a Zacks Rank #4 (Sell), investors should exercise caution as the stock is expected to underperform in the near term.
• The upcoming management commentary on the earnings call is a critical catalyst; any decision to buy, hold, or sell should be deferred until after assessing their guidance on future profitability and revenue trends.
• Investors should monitor for any post-earnings revisions to consensus estimates for coming quarters, as a positive shift could signal a bottom, while further downgrades would reinforce the bearish case.
• Considering the stock's 8.5% YTD loss against the S&P 500's gain, existing holders may consider reducing exposure, especially if management fails to present a credible turnaround plan.